Correction to: J Hematol Oncol (2021) 14:121 https://doi.org/10.1186/s13045-021-01111-4
The original article [1] incorrectly states that OMO-1 is a MYC inhibitor in two instances: in the Direct MYC Inhibition sub-section of the MYC Inhibitors section, and in Table 3.
The authors wish to clarify that OMO-1 is not a MYC inhibitor, and its mentions in the original article should be disregarded.
Reference
Ahmadi SE, et al. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14:121. https://doi.org/10.1186/s13045-021-01111-4.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ahmadi, S.E., Rahimi, S., Zarandi, B. et al. Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14, 135 (2021). https://doi.org/10.1186/s13045-021-01152-9
Published:
DOI: https://doi.org/10.1186/s13045-021-01152-9